Skip to main content

Table 1 Antimicrobial susceptibility profiles.R, resistant; I, intermediate; S, susceptible

From: Comparative genomic analysis of Acinetobacter baumannii clinical isolates reveals extensive genomic variation and diverse antibiotic resistance determinants

Antimicrobial classes Antimicrobial drugs MIC (mg/L) and Susceptibility
BJ1 BJ2 BJ3 BJ4 BJ5 BJ6 BJ7 BJ8
Aminoglycosides Gentamicin (CN) >8, R >8, R >8, R ≤1, S >8, R >8, R >8, R >8, R
Amikacin (AK) ≤16, S >32, R >32, R ≤2, S >32, R ≤16, S ≤16, S >32, R
Antipseudomonal carbapenems Imipenem (IPM) >8, R >8, R >8, R ≤1, S >8, R >8, R >8, R ≤1, S
Antipseudomonal fluoroquinolones Ciprofloxacin (CIP) >2, R >2, R >2, R ≤0.25, S >2, R >2, R >2, R >2, R
Lavo-ofloxacin (LEV) >4, R >4, R >4, R ≤0.25, S >4, R >4, R >4, R =4, I
Antipseudomonal penicillins and β-lactamase inhibitors Piperacillin-tazobactam (TZP) >64/4, R >64/4, R >64/4, R ≤4, I >64/4, R >64/4, R >64/4, R ≤16/4, S
Extended-spectrum cephalosporins Ceftriaxone (CTR) >32, R >32, R >32, R 8, R >32, R >32, R >32, R >32, R
Ceftazidime (CAZ) >16, R >16, R >16, R 4, I >16, R >16, R >16, R >16, R
Cefepime (FEP) >16, R >16, R >16, R 2, S >16, R >16, R >16, R >16, R
Polymyxins Polymyxin B (PB) ≤2, S ≤2, S ≤2, S ≤2, S ≤2, S ≤2, S ≤2, S ≤2, S
Tetracyclines Tetracycline (TE) =8, I >8, R >8, R ≤4, S >8, R >8, R >8, R >8, R